Skip to main content
. 2018 Sep 14;9(72):33634–33647. doi: 10.18632/oncotarget.25950

Figure 3. Circulating levels of LIF and tumoural levels of LIFR are significantly altered in OAC patients with a subsequent poor response to neo-adjuvant treatment.

Figure 3

(A) Circulating LIF in pre-treatment serum of OAC patients was assessed by ELISA. Patients were divided into good (TRG 1/2) (n=10) and poor responders (TRG 3/4/5) (n=16) based on pathological response to neo-adjuvant treatment. (B) Relative mRNA expression of tumoural LIF in OAC pre-treatment biopsies from good (TRG 1/2) (n=11) and poor (TRG 3/4) (n=9) responders (n=20). (C) Relative mRNA expression of tumoural LIFR in OAC pre-treatment biopsies from good (TRG 1/2) (n=6) and poor (TRG 3/4) (n=10) responders. Statistical analysis was performed by Mann-Whitney U test. *p<0.05, ***p<0.001.